12th February 2020 Editorial by: Paul Carton
Austrian and Chinese Biotech Partners Make 2019-nCoV NGS and RT-PCR Testing Available in Europe
The first officially approved technology in China for surveillance, discovery and identification of unknown infectious diseases will now be made available in Europe through a collaboration between Austrian and Chinese Biotech companies. Ares Genetics, an Austrian digital diagnostics company, who are part of the German Curetis Group, will work with the BGI Group, a Chinese genomics company, the designers of a recently approved 2019-nCoV RT-PCR kit.
BGI's 2019-nCoV RT-PCT kit was designed after their subsidiary MGI Tech sequenced the virus using its DNBSEQ-T7 sequencing platform, which was given emergency approval by the Chinese National Medical Products Administration (NMPA). Ares Genetics will now use this sequencing platform in their laboratory in Vienna, Austria. The Curetis group will assist the BGI group, who also have offices and laboratories in Denmark, with the distribution of NGS and PCR reagents to sequence and detect unknown viruses from February 2020 onwards.
Date Published: 12th February 2020
Co-Diagnostics CoPrimer™ is Applied
Roche Distribute Tib-Molbiol Wuhan Coronavirus